NCT04222413
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have progressed on or after at least one line of standard systemic chemotherapy
Exclusions: Patients with central nervous system (CNS) metastases
https://clinicaltrials.gov/show/NCT04222413